Replies to post #11233 on DNAprint Genomics (DNAG)

[mingwan0]

Frog, well that's funny because you didn't disagree 18 months ago, and yes you can count on me correcting you when you are wrong. Let's see when we were in agreement:

Frogdreaming said "I was trying to suggest that it was possible to interpret the contract in such a way that would preclude any imminent deals in regard to Retinome. Therefore, any recent changes in the stock price might not be the result of a previously negotiated deal with a third party, as the board was speculating." Yes, I agree with you.

I can always resurrect the post concerned, blah blah blah...

[trader guy]

Frog,

You said:
It's doubtful that a company with any concept of fiscal responsibility would squander a potentially valuable option on the possibility that a patent 'might' be awarded in a few YEARS. So even if they liked the concepts in the patent application and coveted the technology therein, why would they allow their option 'window' to commence on such a tenuous promise? Why wouldn't they demand the actual patent award to start the clock?

Excellent anology for why no large pharma, small pharma, or any pharma for that matter has come forward and offered any kind of a deal with Dnap. It all looks very promising but Orchid (or Beckman Colter) holds all the cards. Until that matter is resolved it is still just a waiting game. And we may, as you said, be waiting years. How many is anyones guess.

For now, we'll just have to settle for high profile forensics cases. Pretty exciting but far from wildly profitable.

Iom